Volume 11, Number 2—February 2005
Dispatch
Malaria Epidemic and Drug Resistance, Djibouti
Christophe Rogier*
, Bruno Pradines*, H. Bogreau*, Jean-Louis Koeck†‡, Mohamed-Ali Kamil§, and Odile Mercereau-Puijalon¶
, Bruno Pradines*, H. Bogreau*, Jean-Louis Koeck†‡, Mohamed-Ali Kamil§, and Odile Mercereau-Puijalon¶
Table 3
In vitro drug sensitivity of 27 Plasmodium falciparum isolates collected in Djibouti, 1999
| Drugs | Isolates studied (n) | Mean IC50* | 95% confidence interval | Cut-off value | % resistant isolates |
|---|---|---|---|---|---|
| Chloroquine | 27 | 326 nmol/L | 224–474 nmol/L | >100 nmol/L | 93 |
| Amodiaquine | 27 | 10.0 nmol/L | 8.0–12.6 nmol/L | >80 nmol/L | 0 |
| Cycloguanil | 24 | 13 nmol/L | 8–21 nmol/L | >500 nmol/L | 4 |
| Pyrimethamine | 25 | 69 nmol/L | 41–117 nmol/L | >2,000 nmol/L | 4 |
*The 50% inhibitory concentration (IC50) of chloroquine diphosphate, amodiaquine, pyrimethamine dihydrochloride, and cycloguanil, i.e., the drug concentration corresponding to 50% of the uptake of 3H-hypoxanthine by the parasites in drug-free control wells, was determined by nonlinear regression analysis of log-dose/response curves. Mean IC50 and proportion of resistant isolates according to cut-off values are indicated. Data were expressed as the geometric mean IC50 and 95% confidence intervals were calculated.
Page created: April 26, 2011
Page updated: April 26, 2011
Page reviewed: April 26, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.